Re: Role of Tamsulosin, Tadalafil and Silodosin as the Medical Expulsive Therapy in Lower Ureteric Stone: A Randomized Trial (A Pilot Study)
Abstract
Renal transplant stone disease is a rare complication with a reported incidence ranging between 0.2% and 6.3%. However, consequences of allograft lithiasis might be serious leading to acute renal failure if obstruction occurs. In this retrospective study, the authors have evaluated the efficacy and safety of the minimally invasive procedures used to manage cases of allograft lithiasis in 19 patients (1.2%) out of 1615 kidney allograft recipients. Percutaneous nephrolithotomy has been the most frequent choice of treatment modality (31.6%) besides extracorporeal shock wave lithotripsy, flexible ureterorenoscopy, conservative management or combination of those modalities which have rendered stone-free rates in all patients in this cohort. However, it must be kept in mind that immunosuppressed state, the extra anatomic location of the transplanted kidney and denervation of the allograft can make the diagnosis and management challenging in renal transplant nephrolithiasis.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.